Serplulimab, Zynyz (retifanlimab) and danicopan are among the new products that the European Medicines Agency has begun reviewing for potential pan-EU marketing approval.
Serplulimab, from Henlius Biotech, is an anti-PD-1 monoclonal antibody (mAb) for use in combination with chemotherapy (carboplatin and etoposide) for...








